Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 833

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 3
Chunk 833
---
al antibodies. His broader portfolio spans private equity, venture capital, and real
estate investments.  In addition to his work with Multiplier Capital, Mr. Friedberg manages diverse investments and businesses
through Liberty Peak Capital, Key Recovery Group, and related entities. A graduate of Johns Hopkins University, he is also deeply
committed to civic engagement, having founded and actively served on the boards of several community organizations, including
a nonprofit mentoring agency. His extensive investment expertise and understanding of our industry were key factors in his selection
to our board of directors.

Dr.
Richard Malamut has served as a member of our board of directors since January 2023. Dr. Malamut is currently Chief Medical
Officer at MedinCell Inc. He was most recently Chief Medical Officer and Executive Vice President at Collegium Pharmaceuticals
from April 2019 to May 2022 and has also served as Chief Medical Officer for Braeburn Pharmaceuticals, Inc. from 2018 to 2019
where he was responsible for the company’s medical affairs, non-clinical and clinical development, clinical operations,
research and development quality assurance, and pharmacovigilance functions. Prior to that, Dr. Malamut had similar responsibilities
as Chief Medical Officer at Avanir Pharmaceuticals from 2016 to 2018 and was Senior Vice President of Global Clinical Development
at Teva Pharmaceutical Industries Ltd from 2013 to 2016 where he was responsible for Pain, Neuropsychiatry, Oncology, and New
Therapeutic Entities. His experience also includes roles of increasing responsibility focusing on early clinical development and
translational medicine in Neurology, Psychiatry and Analgesia at Bristol-Myers Squibb and AstraZeneca. Dr. Malamut earned his
medical degree from Hahnemann University in Philadelphia and completed both a residency in Neurology and a fellowship in neuromuscular
disease. He worked as a board-certified academic and clinical neurologist for 17 years and has more than 50 publications in the
fields of pain medicine, neuromuscular disease, autonomic disease, and neurodegenerative disease. He was selected to serve on
our board of directors due to his experience and knowledge of our industry.

83 

Chia-Lin
Simmons has served as a member of our board of directors since March 2023. Since June 2021, Ms. Simmons has served
as Chief Executive Officer and as a